Pune, India, March 2019 /MRFR Press Release/- Market Research Future published a half-cooked research report on the global fertility drug and surgery market.
The global fertility drug and surgery market is expected to grow at an approximate CAGR of 9.8% during the forecast period of 2018–2023.
Infertility is a condition when a couple can't get pregnant despite having unprotected sex. Infertility may cause due to a defect in a reproductive system such as abnormal production of sperm due to sexually transmitted diseases or other factors.
There are various symptoms faced by infertile men and woman. In woman the irregular menstrual periods, hormone fluctuation, and in men the semen abnormalities, pelvic infections or sexually transmitted diseases are the common symptoms.
The key factors responsible for driving the market growth are an increase in global infertility rates, increasing obesity, delayed pregnancies in women, increase in gamete donations, increase in disposable income, also rising healthcare expenditure worldwide is promoting the market growth.
The increasing cases of infertility due to a sedentary lifestyle and other factors may boost the demand for fertility treatment products and drive the market growth.
There are various treatment & diagnosis methods to cure this problem for both male and female patient.
In 2017, Merck KGaA announced that the European Commission granted approval for the company’s new Pergoveris pen. This product was the first product with a Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) combination in a ready–to use liquid form.
However, the factors such as cost constraints, complications related to treatments and low awareness level among the population may boost the market growth during the forecasted period.
The global fertility drug and surgery market are segmented on the basis of underlying cause, drug, procedures, end user, and region.
On the basis of the underlying cause, the global fertility drug and surgery market is segmented into male and female. By drug, the global fertility drug and surgery market is categorized into clomiphene citrate, letrozole, Serophene, hormone treatment, gonadotrophins
aromatase inhibitors, estrogen receptor modulators, dopamine agonists, metformin hydrochloride and others. On the basis of procedures, the global fertility drug and surgery market is segmented into hysteroscopy, laparoscopy and robotic laparoscopy, laparotomy/open surgery, egg retrieval, varicocelectomy, vasectomy reversal (vasovasostomy or vasoepididymostomy), sperm retrieval (epididymal aspiration). By end-user, the global fertility drug and surgery market is categorized into fertility clinics, hospitals, clinical research institutes, and others.
On the basis of region, the global fertility drug and surgery market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to hold the largest market share and the Middle East & Africa with a low market share during the forecasted period.
Browse Complete Report Details @ https://www.marketresearchfuture.com/reports/fertility-drug-surgery-market-7588
The Americas dominates the global market for fertility drug and surgery owing to the growing female geriatric population, increase in gamete donations, an increase in clinical research within the region. Additionally, the increasing awareness about the fertility treatment and presence of developed economies and healthcare sector within the region dives the market growth during the forecast period. In 2017, it was estimated that Europe stood second in the global fertility drug and surgery market due to the increasing prevalence of sexually transmitted diseases such as gonorrhea, chlamydia, mumps, and others which produces the abnormal sperm. Asia-Pacific was the fastest growing region for the global fertility drug and surgery market in 2017. Factors such as increased innovation and awareness about the available treatment methods fuel the market growth within the region.
On the other hand, the Middle East and Africa hold the least share in the global fertility drug and surgery market. The presence of poor economies and low per capita income, especially within the African region make the market to lag within the region. A majority of the market share within this region is estimated to be held by the Middle East.
Some of the key players in the global fertility drug and surgery market are Eli Lilly, Baxter Healthcare Corporation, Ferring Pharmaceuticals, Inc., Merck & Co. Pharmaceutical Company, Noven Pharmaceuticalorganon, Inc., Janssen Pharmaceuticals Inc., Personal Products Company, Pfizer, Inc., Procter & Gamble Pharmaceuticals, Emd Serono, Inc., and others.